HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) A correction has been published Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sarkar, S. Articles by Kuper, J. Search for Related Content PubMed PubMed Citation Articles by Sarkar, S. Articles by Kuper, J.

SOHINI SARKAR, PHARM.D., is Clinical Assistant Professor, Lake Erie College of Osteopathic Medicine, Erie, PA; at the time of writing she was Specialized Resident, Drug Information Service, Robert Wood Johnson University Hospital (RWJUH), New Brunswick, NJ. EVELYN R. HERMES DESANTIS, PHARM.D., BCPS, is Director, Drug Information Service, RWJUH, and Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway. JEFF KUPER, PHARM.D., BCPS, is Medical Writer, Pharm-Write, Bridlington, United Kingdom; at the time of writing he was Assistant Director, Clinical Services, RWJUH.

Address correspondence to Dr. Hermes DeSantis at the Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854 (ehermesd{at}rci.rutgers.edu).

Purpose. The role of colistin in the treatment of infections caused by multidrug-resistant gram-negative microorganisms is discussed. Summary. Colistin is structurally and pharmacologically related to polymyxin B, the other commercially available drug from the polymyxin class. Colistin is bactericidal in nearly all strains of gram-negative bacilli. As with all antibiotics, resistance is of paramount concern. Resistance to colistin has not been frequently documented. Colistin must be administered parenterally, as it is not absorbed from the gastrointestinal tract, mucous membranes, or intact or denuded skin. Parenteral colistin has been replaced by less-toxic antibiotics and should be reserved for life-threatening infections caused by organisms resistant to preferred drugs. A number of published studies and case reports have reevaluated the safety and efficacy of parenteral colistin use in patients with multidrug-resistant infections. In three case series, 58–74% of patients exhibited a clinical response to colistin. Although colistin was previously viewed as reasonably effective but highly nephrotoxic, recent studies have suggested that nephrotoxicity may not be as severe as once thought. Frequent renal function monitoring is necessary in patients receiving colistin, since adverse renal effect may occur, regardless of the dosage given. The recommended dosage of parenteral colistin for adults and children with normal renal function is 2.5–5 mg/kg/day, administered as two to four divided doses. Doses must be adjusted for renal impairment, and dosing recommendations for patients undergoing renal replacement therapy have not been well established. Conclusion. With vigilant monitoring of renal function and the avoidance of concomitant neurotoxic medications, colistin can be used safely and effectively with minimal adverse outcomes. Index terms: Absorption; Antiinfective agents; Colistin; Dosage; Drug administration; Gram-negative bacterial infections; Injections; Kidney diseases; Mechanism of action; Pediatrics; Pharmacokinetics; Resistance; Toxicity

 

This article has been cited by other articles:

				S. Sun, A. Negrea, M. Rhen, and D. I. Andersson Genetic Analysis of Colistin Resistance in Salmonella enterica Serovar Typhimurium Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2298 - 2305. [Abstract] [Full Text] [PDF]

				H. J. Warshakoon, M. R. Burns, and S. A. David Structure-Activity Relationships of Antimicrobial and Lipoteichoic Acid-Sequestering Properties in Polyamine Sulfonamides Antimicrob. Agents Chemother., January 1, 2009; 53(1): 57 - 62. [Abstract] [Full Text] [PDF]